384 VICTORIA STREET
Darlinghurst, New South Wales 2010
Australia
Garvan Institute of Medical Research
SARS CoV2 Variants, immunotherapeutics, ACE2, TMPRSS2, Omicron
SARS-CoV-2, neutralising antibodies, RBD, memory B cells
SARS-CoV-2, 12 months after SARS-CoV-2 infection, RBD-specific memory B cells, protection efficacy prediction, SARS-CoV-2 antibodies, SARS-CoV-2 neutralisation, variants of concern, Delta variant